JP2003519164A - ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤 - Google Patents

ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤

Info

Publication number
JP2003519164A
JP2003519164A JP2001549618A JP2001549618A JP2003519164A JP 2003519164 A JP2003519164 A JP 2003519164A JP 2001549618 A JP2001549618 A JP 2001549618A JP 2001549618 A JP2001549618 A JP 2001549618A JP 2003519164 A JP2003519164 A JP 2003519164A
Authority
JP
Japan
Prior art keywords
peptide
polymer
poly
release
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001549618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003519164A5 (https=
Inventor
ベー． コーン、ヨアヒム
エム． シャクター、デボラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of JP2003519164A publication Critical patent/JP2003519164A/ja
Publication of JP2003519164A5 publication Critical patent/JP2003519164A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001549618A 1999-12-31 2001-01-02 ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤 Pending JP2003519164A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17413799P 1999-12-31 1999-12-31
US60/174,137 1999-12-31
PCT/US2001/000030 WO2001049249A2 (en) 1999-12-31 2001-01-02 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix

Publications (2)

Publication Number Publication Date
JP2003519164A true JP2003519164A (ja) 2003-06-17
JP2003519164A5 JP2003519164A5 (https=) 2011-04-28

Family

ID=22634986

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001549618A Pending JP2003519164A (ja) 1999-12-31 2001-01-02 ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤

Country Status (5)

Country Link
EP (1) EP1263453A4 (https=)
JP (1) JP2003519164A (https=)
AU (1) AU784226B2 (https=)
CA (1) CA2396037A1 (https=)
WO (1) WO2001049249A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528866A (ja) * 2009-06-01 2012-11-15 タイレックス・インコーポレイテッド 胸骨創感染症を予防するための組成物および方法
JP2013501106A (ja) * 2009-07-31 2013-01-10 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー 天然代謝産物のモノマー類似体から合成された生体吸収性ポリマー

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7326425B2 (en) 1999-12-31 2008-02-05 Rutgers, The State University Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US8315700B2 (en) 2006-02-08 2012-11-20 Tyrx, Inc. Preventing biofilm formation on implantable medical devices
EP2114298B1 (en) 2006-02-08 2022-10-19 Medtronic, Inc. Temporarily stiffened mesh prostheses
US9265865B2 (en) 2006-06-30 2016-02-23 Boston Scientific Scimed, Inc. Stent having time-release indicator
US9023114B2 (en) 2006-11-06 2015-05-05 Tyrx, Inc. Resorbable pouches for implantable medical devices
MX2009004821A (es) 2006-11-06 2009-11-23 Tyrx Pharma Inc Bolsas de malla para dispositivos medicos implantables.
AU2008232682B2 (en) 2007-03-29 2013-03-21 Medtronic, Inc. Biodegradable, polymer coverings for breast implants
MX2009011785A (es) 2007-05-02 2010-03-04 Tyrx Pharma Inc Polimeros de dihidroxibenzoato y usos de los mismos.
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2630406T3 (es) 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8652525B2 (en) 2008-07-10 2014-02-18 Tyrx, Inc. NSAID delivery from polyarylates
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2737769C (en) 2008-09-22 2014-02-04 Medtronic, Inc. Linear polyesteramides from aminophenolic esters
US9839628B2 (en) 2009-06-01 2017-12-12 Tyrx, Inc. Compositions and methods for preventing sternal wound infections
US8409279B2 (en) 2009-10-01 2013-04-02 Lipose Corporation Breast implant implantation method and apparatus
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
JP6031033B2 (ja) 2010-08-25 2016-11-24 タイレックス・インコーポレイテッドＴｙｒｘ Ｉｎｃ． 医療デバイスの新規なコーティング
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2011326417A1 (en) 2010-11-12 2013-05-09 Tyrx, Inc. Anchorage devices comprising an active pharmaceutical ingredient
AU2012283875B2 (en) 2011-07-20 2016-05-12 Medtronic, Inc. Drug eluting mesh to prevent infection of indwelling transdermal devices
CA2879982C (en) 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014137454A1 (en) 2013-03-07 2014-09-12 Tyrx, Inc. Methods and compositions to inhibit the assemblage of microbial cells irreversibly associated with surfaces of medical devices
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN106061494A (zh) 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
WO2015069305A1 (en) 2013-11-08 2015-05-14 Tyrx, Inc. Antimicrobial compositions and methods for preventing infection in surgical incision sites
EP3177319A1 (en) * 2014-08-04 2017-06-14 Janssen Sciences Ireland UC Compacted solid dosage form
WO2017123634A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024107A1 (en) * 1997-11-07 1999-05-20 Rutgers, The State University Biodegradable, anionic polymers derived from the amino acid l-tyrosine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587507A (en) * 1995-03-31 1996-12-24 Rutgers, The State University Synthesis of tyrosine derived diphenol monomers
US5658995A (en) * 1995-11-27 1997-08-19 Rutgers, The State University Copolymers of tyrosine-based polycarbonate and poly(alkylene oxide)
MXPA99007662A (es) * 1997-02-18 2002-07-22 Univ Rutgers Monomeros derivados de hidroxiacidos, y polimeros preparados a partir de los mismos.
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
ZA9811377B (en) * 1997-12-12 1999-08-27 Expression Genetics Inc Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid[ for the delivery of a bioactive agent via tissue and cellular uptake.
EP1073688B1 (en) * 1998-04-13 2015-03-04 Rutgers, The State University The construction of copolymer libraries
JP2002536695A (ja) * 1999-02-05 2002-10-29 エイリアン・テクノロジイ・コーポレーション アセンブリを形成するための装置および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024107A1 (en) * 1997-11-07 1999-05-20 Rutgers, The State University Biodegradable, anionic polymers derived from the amino acid l-tyrosine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528866A (ja) * 2009-06-01 2012-11-15 タイレックス・インコーポレイテッド 胸骨創感染症を予防するための組成物および方法
JP2013501106A (ja) * 2009-07-31 2013-01-10 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー 天然代謝産物のモノマー類似体から合成された生体吸収性ポリマー

Also Published As

Publication number Publication date
WO2001049249A2 (en) 2001-07-12
AU2925501A (en) 2001-07-16
EP1263453A2 (en) 2002-12-11
AU784226B2 (en) 2006-02-23
WO2001049249A3 (en) 2002-01-17
EP1263453A4 (en) 2008-02-20
CA2396037A1 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
JP2003519164A (ja) ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤
JP4917726B2 (ja) ポリマー混合物および活性化合物からなる徐放用医薬製剤
US7521061B2 (en) Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
US6589548B1 (en) Controlled drug delivery system using the conjugation of drug to biodegradable polyester
RU2152225C1 (ru) Микрочастицы, включающие соли пептидов с полиэфирами, имеющими концевые карбоксигруппы, и содержащие их композиции
JP6195587B2 (ja) 低バーストポリ−（ラクチド／グリコシド）およびポリマーを生成するための方法
CN103827177B (zh) 用于生物活性化合物的受控释放的生物可降解的、半结晶的、相分离的、热塑性多嵌段共聚物
ES2628931T3 (es) Copolímeros multibloque segmentados de fases separadas biodegradables y liberación de polipétidos biológicamente activos
JP2000500803A (ja) トリブロック共重合体を基材とする新規なヒドロゲル、その製造及びその用途
Park et al. Cationic and thermosensitive protamine conjugated gels for enhancing sustained human growth hormone delivery
CN111511385B (zh) 具有选定的释放持续时间的药物组合物
EP1932870A1 (en) Biocompatible block copolymer, use thereof, and production method thereof
US20100172950A1 (en) Pharmaceutical compositions comprising dextran with a molecular weight of 1.0-100 kda and processes for their preparation
KR100752702B1 (ko) 생분해성 고분자 나노입자 및 그 제조방법
Cheng et al. Thermo-Sensitive mPEG-PA-PLL Hydrogel for Drug Release of Calcitonin. Gels 2022, 8, 282
Singh Smart polymer-based controlled-release drug-delivery systems for peptide and protein
US20050271699A1 (en) Biodegradable composition with prolonged release of the biological active compound and preparation thereof
Svenson Advances in polymeric matrices and drug particle engineering
Joung et al. Novel Hydrogel Systems as Injectable Scaffolds for Tissue Engineering
GELATORS I. Polymeric Materials for Drug Delivery
Stankovic et al. Protein release from water-swellable poly (D, L-lactide-PEG)-b-poly

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110303

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110928

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111206

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120306

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120313

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120803